Table 3.

Univariate and multivariate analyses for anti-RBD-IgG in PLWH.

Variable	Univariate OR (95% CI)	P value	Multivariate OR (95% CI)	P value
Age (years)	0.995 (0.970-1.020)	0.696	0.985 (0.954-1.018)	0.382
Gender (male)	0.712 (0.384-1.319)	0.280	0.963 (0.422-2.197)	0.928
Days after 2nd dose Vaccination	0.978 (0.966-0.991)	0.001	0.969 (0.953-0.983)	0.000
Plasma HIV viral load
>20 copies/mL	1.498 (0.728-3.083)	0.272	2.104 (0.861-5.140)	0.103
CD4 count (cells/µL)
<200	0.284 (0.106-0.758)	0.012	0.206 (0.053-0.797)	0.022
200–500	0.640 (0.332-1.230)	0.180	0.517 (0.231-1.160)	0.109
White blood cell count (10^9/L)	1.013 (0.829-1.237)	0.903
Lymphocyte count (10^9/L)	0.979 (0.944-1.016)	0.266	0.972 (0.918-1.031)	0.350
Platelet count (10^9/L)	1.002 (0.998-1.006)	0.378
Alanine aminotransferase (U/L)	0.990 (0.969-1.010)	0.333
Aspartate aminotransferase (U/L)	0.990 (0.967-1.014)	0.403
B cells (% of lymphocytes)	0.989 (0.884-1.105)	0.841
RBD-specific B cells (%)	0.984 (0.919-1.053)	0.638
RBD-specific MBCs (%)	0.985 (0.959-1.013)	0.294	0.161 (0.023-1.138)	0.067
RBD+ rMBCs (%)	0.973 (0.929-1.020)	0.264	0.163 (0.0001-241.290)	0.626
RBD+ actMBCs (%)	0.982 (0.932-1.035)	0.491	0.184 (0.0001-274.513)	0.650
RBD+ atyMBCs (%)	1.002 (0.953-1.053)	0.936	0.027 (0.00001-53.250)	0.351
RBD+ intMBCs (%)	1.017 (0.986-1.049)	0.285	0.028 (0.00001-55.202)	0.355

CI, confidential interval; OR, odds ratio.